Cibus Q2 revenue rises, loss narrows on cost cuts

Cibus

13/08/2026 21:18

Overview
US agri-biotech firm's Q2 revenue rose yr/yr but missed analyst expectations
Net loss per share narrowed to $0.29 from $0.61 a year ago on cost cuts
Quarterly net cash usage fell 19% sequentially and 31% yr/yr

Outlook
Cibus targets initial Rice trait launches in LATAM in 2028 and U.S. in 2029
Company expects additional scale-up orders for biofragrances in H2 2026
Cibus projects annual net cash usage run-rate of about $35 mln exiting 2026

Result Drivers
COST REDUCTION INITIATIVES - Co said lower R&D and SG&A expenses were primarily due to cost-saving measures
SUSTAINABLE INGREDIENTS PROGRAM - Co said revenue generation continued from commercial ramp-up with consumer-products partner
RICE COMMERCIALIZATION - Co said it advanced Rice herbicide tolerance traits and expanded the contemplated Interoc relationship from two traits to five

Company press release: ID:nGNXDd1gG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$994,000
$1.70 mln (2 Analysts)
Q2 Loss Per Share
 
$0.29
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cibus Inc is $16.00, about 746.6% above its August 12 closing price of $1.89

Reuters Recommended Reads
Aug 13 - 22nd Century Q2 revenue falls on product shift
Aug 12 - USDA raises US 2026 corn, soy production estimates
Aug 12 - Simris Alg Q2 EBITDA loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)